Abstract
Lonidamine was given for 3 weeks at the dose of 150 mg three times daily to 6 male cancer patients. Serum follicle-stimulating and luteinizing hormone levels were significantly higher as compared to pretreatment values after 1 and 3 weeks of Lonidamine administration, while testosterone, prolactin, and thyroid-stimulating hormone levels remained unchanged.
MeSH terms
-
Aged
-
Antispermatogenic Agents / pharmacology*
-
Follicle Stimulating Hormone / blood
-
Humans
-
Indazoles / pharmacology*
-
Luteinizing Hormone / blood
-
Male
-
Middle Aged
-
Pituitary Gland / drug effects
-
Pituitary Gland / physiology*
-
Prolactin / blood
-
Pyrazoles / pharmacology*
-
Testis / drug effects
-
Testis / physiology*
-
Thyroid Hormones / blood
-
Time Factors
Substances
-
Antispermatogenic Agents
-
Indazoles
-
Pyrazoles
-
Thyroid Hormones
-
Prolactin
-
Luteinizing Hormone
-
Follicle Stimulating Hormone
-
lonidamine